%PDF-1.4
%
44 0 obj
<>
endobj
41 0 obj
<>
endobj
92 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-30T09:05:34Z
2024-03-29T08:33:53-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T08:33:53-07:00
application/pdf
Heather
2002-971.sept
uuid:501abd1a-1dd2-11b2-0a00-780827edca00
uuid:501abd1c-1dd2-11b2-0a00-380000000000
endstream
endobj
30 0 obj
<>
endobj
31 0 obj
<>
endobj
45 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 18 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 20 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
106 0 obj
[110 0 R]
endobj
107 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.33051 Tw 10 0 0 10 54 713.1616 Tm
(ables, age, and inhibition of thrombin generation were)Tj
0.02499 Tw 0 -1.2 TD
[(significantly associated with )17.7 (VTE disease. )]TJ
0.1588 Tw 1.2 -1.2 Td
(Previous studies of patients presenting with new onset)Tj
-0.0195 Tw -1.2 -1.2 Td
(VTE disease have reported a significant association with the)Tj
0 Tw T*
(LAC)Tj
0 Tc 6.5 0 0 6.5 73.9976 668.4615 Tm
(16,17)Tj
-0.00011 Tc 0.0089 Tw 10 0 0 10 91.2118 665.1616 Tm
(but not with the presence of aCL)Tj
0 Tc 0 Tw 6.5 0 0 6.5 222.8123 668.4615 Tm
(16,18)Tj
-0.00011 Tc -0.0459 Tw 10 0 0 10 237.4371 665.1616 Tm
[(. Although )-54.9 (we)]TJ
0.02679 Tw -18.3437 -1.2 Td
[(did not measure the LAC in this study)64.8 (, there was an associ-)]TJ
0.0105 Tw T*
[(ation between the occurrence of )17.7 (VTE disease and inhibition)]TJ
0.093 Tw T*
[(of thrombin generation. )17.7 (W)79.9 (e have previously shown that in)]TJ
0.1041 Tw T*
(patients with autoimmune aPL, abnormalities in this func-)Tj
-0.0321 Tw T*
(tional assay correlate with the presence of the LAC and have)Tj
0.134 Tw T*
[(a strong association with )17.7 (VTE disease)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 212.9677 596.4615 Tm
(15)Tj
-0.00011 Tc 0.134 Tw 10 0 0 10 219.4676 593.1616 Tm
(. Our current data)Tj
-0.0145 Tw -16.5468 -1.2 Td
(suggest that this assay may also detect a subtle procoagulant)Tj
0.1586 Tw T*
(diathesis in unselected patients presenting with idiopathic)Tj
0.02499 Tw T*
(VTE disease. )Tj
0.2516 Tw 1.2 -1.21 Td
(The mechanism responsible for the observed )Tj
/T1_1 1 Tf
19.669 0 Td
[(in vitr)36.8 (o)]TJ
/T1_0 1 Tf
-0.0191 Tw -20.869 -1.21 Td
(inhibition of thrombin generation and how this phenomenon)Tj
0.0757 Tw 0 -1.21 TD
[(may promote a procoagulant state is unclear)54.8 (. In the )54.8 (APS it)]TJ
-0.00951 Tw T*
(has been proposed that aPL, specifically anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 240.2979 505.4616 Tm
(2)Tj
-0.00011 Tc -0.00951 Tw 10 0 0 10 243.5479 508.7617 Tm
(-GPI, inhibit)Tj
0.041 Tw -18.9548 -1.21 Td
[(the binding of annexin )17.7 (V)-273.3 (to cell surface negatively char)17.7 (ged)]TJ
0.0791 Tw T*
(phospholipids, thereby allowing a permissive procoagulant)Tj
0.02521 Tw T*
[(state. Conversely)64.8 (, )]TJ
/T1_1 1 Tf
[-0.4 (in vitr)36.7 (o)]TJ
/T1_0 1 Tf
10.5519 0 Td
[(binding of aPL)-238.5 (to synthetic phos-)]TJ
0.2747 Tw -10.5519 -1.21 Td
(pholipid is responsible for the paradoxical inhibition of)Tj
0.017 Tw T*
[(thrombin generation and LAC activity)64.8 (. In our study)64.8 (, plasma)]TJ
0.1107 Tw T*
[(samples from patients with )17.7 (VTE disease caused inhibition)]TJ
0.0235 Tw T*
[(of annexin )17.8 (V)-255.6 (binding to CL, although the magnitude of this)]TJ
0.0408 Tw T*
(inhibition was markedly less than that seen in patients with)Tj
0.0006 Tc 0.3743 Tw T*
(autoimmune aPL)Tj
0 Tw 6.5 0 0 6.5 126.4364 403.1618 Tm
(14)Tj
0.3195 Tw 10 0 0 10 132.9454 399.8617 Tm
(. Anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 167.2982 396.5617 Tm
(2)Tj
0.0006 Tc 0.3743 Tw 10 0 0 10 170.5527 399.8617 Tm
(\320GPI could not be causally)Tj
0.0199 Tc 0.43021 Tw -11.6553 -1.21 Td
(implicated in this phenomenon and thus alternative)Tj
-0.00011 Tc 0.1292 Tw T*
(immunologic or non-immunologic serologic factor\(s\) may)Tj
0.1956 Tw T*
(be responsible for this subtle perturbation of coagulation)Tj
0.02499 Tw T*
(and consequent predisposition to )Tj
/T1_1 1 Tf
13.4858 0 Td
(in vivo)Tj
/T1_0 1 Tf
0 Tw 2.9934 0 Td
(thrombosis.)Tj
0.0524 Tw -15.2791 -1.19 Td
(What are the potential implications of these findings for)Tj
0.25101 Tw -1.2 -1.19 Td
(the management of individual patients with thrombosis?)Tj
0.1288 Tw 0 -1.19 TD
(Recent data)Tj
0 Tc 0 Tw 6.5 0 0 6.5 102.2068 319.0618 Tm
(19)Tj
-0.00011 Tc 0.1288 Tw 10 0 0 10 112.4947 315.7618 Tm
[(suggest that annexin-V)-361.1 (binding to phospho-)]TJ
0.0471 Tw -5.8495 -1.19 Td
[(lipid bilayers has suf)17.7 (ficient af)17.7 (finity to displace other bound)]TJ
0.0199 Tc 0.4888 Tw T*
(proteins including anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 167.0822 288.6618 Tm
(2)Tj
0.01981 Tc 10 0 0 10 170.4621 291.9618 Tm
(-GPI-\247)Tj
0 Tc 6.5 0 0 6.5 199.4232 288.6618 Tm
(2)Tj
0.0199 Tc 0.48869 Tw 10 0 0 10 202.8031 291.9618 Tm
(-GPI complexes. In)Tj
-0.00011 Tc 0.1165 Tw -14.8803 -1.19 Td
[(parallel with this observation, )17.7 (Thiagarajan, )]TJ
/T1_1 1 Tf
[-0.4 (et al)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 6.5 0 0 6.5 252.4039 283.3618 Tm
(20)Tj
-0.00011 Tc 0.1165 Tw 10 0 0 10 262.5689 280.0618 Tm
(found a)Tj
0.0199 Tc 0.4106 Tw -20.8569 -1.19 Td
(dose-dependent inhibition of thrombus formation by)Tj
-0.00011 Tc 0.0007 Tw T*
[(annexin )17.7 (V)-232.9 (in a rabbit carotid artery thrombosis model. )17.7 (They)]TJ
0.3532 Tw T*
(proposed that coating of exposed procoagulant anionic)Tj
-0.00481 Tw T*
[(phospholipids on platelets by annexin )17.7 (V)-227.4 (was the most likely)]TJ
0.349 Tw T*
(mechanism of action. Furthermore van Heerde, )Tj
/T1_1 1 Tf
0.34891 Tw [-0.3 (et al)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 6.5 0 0 6.5 287.5001 223.8618 Tm
(21)Tj
-0.00011 Tc -0.0197 Tw 10 0 0 10 54 208.6619 Tm
(showed a reduction in platelet adhesion and fibrin formation)Tj
-0.0083 Tw T*
(on activated endothelial cells in a human )Tj
/T1_1 1 Tf
16.5193 0 Td
(ex vivo)Tj
/T1_0 1 Tf
0 Tw 3.0366 0 Td
(thrombosis)Tj
0.0087 Tw -19.5559 -1.19 Td
[(model by preincubation with annexin )17.7 (V)128.9 (.)-0.1 ( )17.7 (These observations)]TJ
0.29179 Tw T*
[(raise the possibility that annexin )17.7 (V)-524 (may be a valuable)]TJ
0.02499 Tw T*
(adjunctive therapy in acute or resistant thrombosis. )Tj
/T1_2 1 Tf
0 Tw 0 -1.8 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 133.0619 Tm
[(1.)-875.1 (Galli M, Comfurius P)110.7 (, Maassen C, et al. )54.8 (Anticardiolipin antibodies)]TJ
1.675 -1.25 Td
[(\(ACA\) directed not to cardiolipin but to a plasma protein cofactor)54.8 (.)]TJ
0 -1.25 TD
(Lancet 1990;335:1544-7.)Tj
-1.675 -1.225 Td
[(2.)-875.1 (McNeil HP)110.7 (, Simpson RJ, Chesterman CN, Krilis SA. )]TJ
1.675 -1.225 Td
(Anti-phospholipid antibodies are directed against a complex)Tj
0 -1.225 TD
(antigen that includes a lipid-binding inhibitor of coagulation: beta)Tj
T*
[(2-glycoprotein I \(apolipoprotein H\). Proc Natl )54.8 (Acad Sci USA)]TJ
0 Tc 0 Tw 33 80.0834 Td
(1990;87:4120-4.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.225 Td
[(3.)-875.1 (Oosting JD, Derksen RH, Bobbink IW)91.7 (, Hackeng )17.7 (TM, Bouma BN,)]TJ
1.675 -1.225 Td
[(de Groot PG. )54.8 (Antiphospholipid antibodies directed against a )]TJ
T*
(combination of phospholipids with prothrombin, protein C, or)Tj
T*
(protein S: an explanation for their pathogenic mechanism? Blood)Tj
0 Tc 0 Tw T*
(1993;81:2618-25.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.225 Td
[(4.)-875.1 (Permpikul P)110.7 (,)-0.1 ( Rao L)91.7 (V)128.9 (, Rapaport SI. Functional and binding studies)]TJ
1.675 -1.225 Td
(of the roles of prothrombin and beta 2-glycoprotein I in the )Tj
T*
[(expression of lupus anticoagulant activity)64.8 (. Blood 1994;83:2878-92.)]TJ
-1.675 -1.225 Td
[(5.)-875.1 (Del Papa N, Meroni PL, )17.7 (T)35 (incani )54.8 (A, et al. Relationship between)]TJ
1.675 -1.225 Td
(anti-phospholipid and anti-endothelial cell antibodies: further )Tj
T*
(characterization of the reactivity on resting and cytokine-activated)Tj
T*
(endothelial cells. Clin Exp Rheumatol 1992;10:37-42.)Tj
-1.675 -1.225 Td
[(6.)-875.1 (Del Papa N, Guidali L, Sala )54.8 (A, et al. Endothelial cells as tar)17.7 (get for)]TJ
1.675 -1.225 Td
(antiphospholipid antibodies. Human polyclonal and monoclonal)Tj
T*
(anti-beta 2-glycoprotein I antibodies react in vitro with endothelial)Tj
T*
(cells through adherent beta 2-glycoprotein I and induce endothelial)Tj
T*
[(activation. )54.8 (Arthritis Rheum 1997;40:551-61.)]TJ
-1.675 -1.225 Td
[(7.)-875.1 (Simantov R, La Sala JM, Lo SK, et al. )54.8 (Activation of cultured)]TJ
1.675 -1.225 Td
(vascular endothelial cells by antiphospholipid antibodies. J Clin)Tj
T*
[(Invest 1995;96:221)36.8 (1-9.)]TJ
-1.675 -1.225 Td
[(8.)-875.1 (Asano )17.7 (T)74 (, Furie BC, Furie B. Platelet binding properties of )]TJ
1.675 -1.225 Td
(monoclonal lupus autoantibodies produced by human hybridomas.)Tj
0 Tc T*
(Blood 1985;66:1254-60.)Tj
-0.00011 Tc -1.675 -1.225 Td
[(9.)-875.1 (Rauch J, Meng QH, )17.7 (T)69.9 (annenbaum H. Lupus anticoagulant and )]TJ
1.675 -1.225 Td
(antiplatelet properties of human hybridoma autoantibodies. )Tj
T*
(J Immunol 1987;139:2598-604.)Tj
-2.175 -1.225 Td
[(10.)-875.1 (Khamashta MA, Harris EN, Gharavi )54.8 (AE, et al. Immune mediated)]TJ
2.175 -1.225 Td
(mechanism for thrombosis: antiphospholipid antibody binding to)Tj
0 Tc T*
[(platelet membranes. )54.8 (Ann Rheum Dis 1988;47:849-54.)]TJ
-0.00011 Tc -2.1381 -1.225 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Galli M, Ruggeri L, Barbui )17.6 (T)74 (. Dif)17.7 (ferential ef)17.7 (fects of )]TJ
2.1381 -1.225 Td
(anti-beta2-glycoprotein I and antiprothrombin antibodies on the)Tj
T*
(anticoagulant activity of activated protein C. Blood )Tj
0 Tc 0 Tw T*
(1998;91:1999-2004.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(12.)-875.1 (Rand JH, )17.7 (W)39.8 (u)-0.1 ( XX, )54.8 (Andree HA, et al. Pregnancy loss in the)]TJ
2.175 -1.225 Td
(antiphospholipid-antibody syndrome\321a possible thrombogenic)Tj
T*
(mechanism. N Engl J Med 1997;337:154-60.)Tj
-2.175 -1.2375 Td
[(13.)-875.1 (Rand JH, )17.7 (W)39.8 (u)-0.1 ( XX, )54.8 (Andree HA, et al. )54.8 (Antiphospholipid antibodies)]TJ
2.175 -1.2375 Td
[(accelerate plasma coagulation by inhibiting annexin-V)-257.3 (binding to)]TJ
0 -1.2375 TD
(phospholipids: a \322lupus procoagulant\323 phenomenon. Blood)Tj
0 Tc 0 Tw T*
(1998;92:1652-60.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2375 Td
[(14.)-875.1 (Hanly JG, Smith SA. )54.8 (Anti-beta2-glycoprotein I \(GPI\) )]TJ
2.175 -1.2375 Td
[(autoantibodies, annexin )17.7 (V)-257.2 (binding and the anti-phospholipid)]TJ
T*
(syndrome. Clin Exp Immunol 2000;120:537-43.)Tj
-2.175 -1.2375 Td
[(15.)-875.1 (Hanly JG, Smith SA. )54.8 (Anti-beta2-glycoprotein I autoantibodies, in)]TJ
2.175 -1.2375 Td
(vitro thrombin generation, and the antiphospholipid syndrome. )Tj
T*
(J Rheumatol 2000;27:2152-9.)Tj
-2.175 -1.2375 Td
[(16.)-875.1 (Ginsber)17.7 (g JS, )17.7 (W)79.9 (ells PS, Brill-Edwards P)110.7 (, et al. )54.8 (Antiphospholipid)]TJ
2.175 -1.2375 Td
(antibodies and venous thromboembolism. Blood 1995;86:3685-91.)Tj
-2.175 -1.2375 Td
[(17.)-875.1 (Simioni P)110.8 (, Prandoni P)110.7 (, Zanon E, et al. Deep venous thrombosis and)]TJ
2.175 -1.2375 Td
[(lupus anticoagulant. )54.8 (A)-220.1 (case-control study)64.8 (. )17.7 (Thromb Haemost)]TJ
0 Tc 0 Tw T*
(1996;76:187-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2375 Td
[(18.)-875.1 (Anticardiolipin antibodies and the risk of recurrent thrombo-)]TJ
2.175 -1.2375 Td
[(occlusive events and death. )17.7 (The )54.8 (Antiphospholipid )54.8 (Antibodies and)]TJ
T*
[(Stroke Study Group \(AP)91.7 (ASS\). Neurology 1997;48:91-4.)]TJ
-2.175 -1.2375 Td
[(19.)-875.1 (W)39.8 (illems GM, Janssen MP)110.7 (, Comfurius P)110.8 (, Galli M, Zwaal RF)79.7 (, Bevers)]TJ
2.175 -1.2375 Td
[(EM. Competition of annexin )17.7 (V)-257.2 (and anticardiolipin antibodies for)]TJ
T*
(binding to phosphatidylserine containing membranes. Biochemistry)Tj
0 Tc 0 Tw T*
(2000;39:1982-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(20.)-875.1 (Thiagarajan P)110.7 (, Benedict CR. Inhibition of arterial thrombosis by)]TJ
2.175 -1.225 Td
[(recombinant annexin )17.7 (V)-257.2 (in a rabbit carotid artery injury model.)]TJ
0 -1.225 TD
(Circulation 1997;96:2339-47.)Tj
-2.175 -1.225 Td
[(21.)-875.1 (van Heerde )17.7 (WL, Sakariassen KS, Hemker HC, Sixma JJ,)]TJ
2.175 -1.225 Td
[(Reutelingsper)17.7 (ger CP)110.7 (, de Groot PG. )54.8 (Annexin )17.7 (V)-257.2 (inhibits the)]TJ
T*
[(procoagulant activity of matrices of )17.7 (TNF-stimulated endothelium)]TJ
T*
[(under blood flow conditions. )54.8 (Arterioscler )17.7 (Thromb 1994;14;824-30.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Hanly)54.8 (, et al: )17.7 (Annexin binding in venous thr)36.8 (ombosis)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1993)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
24 0 obj
<>stream
8;Z\7d>l*u#ikr7OP`'4%0d`K+fm=ENRMb#Q4hp`TW16RftT9[L5TS^8_r"b_H3\g
Ms[R;72>jsmECRL?fgm-$(,^-h?K@jPLNm'24D2&?]iY:gq[t3T9g-L,`[559;umB
\K9rG;'p`\"i]BO6,(`qi':U&hXAI(cd9):jt-?T>QSZXZ#XJg?YW09ra%VRSE6ET
QBItVC;8qFJ>Nc;2+Nks8DRFPP4mKRTEqiHY*qF\,aCZrZMXO5ZA0jbEn(htlAEO-
PmB*\7<'G;Ad%piEQ)O5-s%$5E7?F?kqF$TL(uZL`Us\/G,OKHY1n,h2%R
H^-R:Q?q8J3ZVnQE@:14&:3YBf$]EiCYEVcSo=J(=-tVXFo/G]T,9\PP@=]U\/)ul
i6NDe9)>bF0-kr5KA*m>lTWou"mK[>'D:QJgIaYO(Q%;7%2+&aBlI#TsI`
1W*$j@g=2SOapQtp%Wp\h'h>U^[[o$ddN+/]2CgUER`qb^cpj8B>4R$(.1@3d*!CH
5EZB<-!^2OQ_[X.,cpLJ9)Z'=Z\n/*??*:@p_LJ\GfT!2Rt'"o^B"
endstream
endobj
28 0 obj
[/Indexed/DeviceRGB 255 27 0 R]
endobj
27 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
52 0 obj
<>
endobj
47 0 obj
<>
endobj
10 0 obj
<>
endobj
83 0 obj
<>
endobj
97 0 obj
<>
endobj
12 0 obj
<>
endobj
13 0 obj
<>stream
HLPw9v_lEY=I1WChBD(ĉs.waAqwTQXQ!S$:$jǤ+ٝgvޙ|]
!HX&mzKjjqɳCe>|^m,C#|gΣ"$HN,Y^V%Z(.-$&>G5Q1BJ}YXW(7:[],rsbAHZC1;bzH`q&\4KMb`/2-6{yUYHyA0
EZLc R}gb"hTGRGD0\1dsȻ!7t.*Ju ܫ)a_;45ܝsE,!K`clk뙣T-%)eUr"|^{JVf!]tBxΰ8!tѺ/w{ "Xv`{-ve?_bExq6DWWyUxB(E܅8e|JCc,,TK4sPD<,6*r29
>Ñݻq#$cKt5vi^Am^JZb_[p`.qsSDR(s(KjѽKfno
[ՅA5:0
DLj8?OZ/[0ZcҀC3EJ( 0B
EfyucMSF +wG2NTHTt_2S0.tyl=';"S Mh߉sڼ]$coCYE[I4Ѿӻ) fG5-r>x%dGza+E-0 kw
endstream
endobj
48 0 obj
<>
endobj
75 0 obj
<>stream
HUkPW|)å+* "
j[A \#D$@א$\UQ]ZmVJٵ:eFw}ٍ?;sf9}!N?Y11kY./8R%xٴؠ8dgޮy'y[mk8+_%NN_<r^M('ocpMHѭ+ֶF^4xq1^U"<9b
de98Hon^Djԕ5'*~Cb>
+HY<5Z Mq{trtYXq8`q|*3C^vK~ɨeˌJքg5ꟶæsWa0{żԵP!3]liv=ܬM+)/5aK9U ]vBLEPuW5}/ tMJqv]vA{A5p>A{?&sLT(qZCY|jfae6